Therapeutic hypothermia (TH), in which body temperature is lowered for an extended period following cardiac arrest, is one of the very few clinically approved therapies to treat the ischemic brain injury that can result from lack of blood flow to the brain. However, TH carries its own risks, such as fluid and electrolyte imbalances, arrhythmia, insulin resistance, and coagulation problems. New drug therapies are desperately needed.